Details of the Drug Combinations

General Information of This Drug (ID: DMUF0BJ)

Drug Name

CYTISINE DMUF0BJ

Synonyms

CYTISINE; 485-35-8; Sophorine; Baptitoxine; (-)-Cytisine; Laburnin; Baptitoxin; Tabex; Ulexin; Cytiton; Ulexine; Tsitizin; Cytitone; Cystisine; Cytizin; Citizin; Tabax; (1R,5S)-3,4,5,6-Tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one; Baphitoxine; UNII-53S5U404NU; Cytisine (-); HSDB 3560; EINECS 207-616-0; NSC 407282; BRN 0083882; Cytisin; (1r,5s)-1,2,3,4,5,6-Hexahydro-8h-1,5-Methanopyrido[1,2-A][1,5]diazocin-8-One; CHEBI:4055; CHEMBL497939; 53S5U404NU; Cytisine, 98%

Indication

Disease Entry	ICD 11	Status	REF
Tobacco dependence	6C4A.2	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

6 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Chloroquine + CYTISINE	DCSRV77	Chloroquine	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
Chloroquine + CYTISINE	DCBNQN3	Chloroquine	Primitive neuroectodermal tumor (Cell Line: TC-32)	[2]
Panobinostat + CYTISINE	DCLJYSH	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
Prazosin + CYTISINE	DCUCTJF	Prazosin	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
SCH 727965 + CYTISINE	DCM1EIT	SCH 727965	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
Ym155 + CYTISINE	DCZGXXI	Ym155	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DrugCom(s)

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Aspirin + CYTISINE	DCVEKJP	Aspirin		[3]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	#N/A